ClinicalTrials.gg
Active, not recruitingNCT05700916Updated Aug 12, 2026

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

An Early Phase 1 interventional study of Milk Polar Lipid-Rich Dairy Powder and Dairy Powder in Dyslipidemias and Obesity, sponsored by University of Connecticut. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by University of Connecticut · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Planned enrollment
139th of 316
130 · median 105
Started
2023
with 13 others
Phase 1
42 of 349
2 open now
Primary completion
2026-12
later than 7 of 33 live
Registered
299th of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 139th largest by planned enrollment of the 316 interventional ones that give a count, is one of 14 that started in 2023, is one of 42 in phase 1, reaches primary completion later than 7 of the 33 other live ones, and was the 299th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

Read the detailed description

The investigators will conduct a randomized, double-blind, controlled, parallel, intervention study in dyslipidemic adults with abdominal obesity (n = 130). Participants will consume either a control dairy beverage (n = 65) or an MPL-rich dairy beverage (n = 65) for 8 weeks. The investigators plan to evaluate the following 4 specific objectives:

  1. Determine the effects of MPLs on serum lipid concentrations and other cardiometabolic risk factors.
  2. Evaluate the effects of MPLs on systemic biomarkers of low-grade inflammation.
  3. Examine the effects of MPLs on lipoprotein metabolism and lipoprotein particle characteristics.
  4. Evaluate the effects of MPLs on gut microbiota, gut permeability markers, and fecal lipids.
03

Conditions studied

  • Dyslipidemias
  • Obesity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LDL-C ≥ 130 mg/dL
  • Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
  • Aged 18 to 70 years

Exclusion criteria

Exclusion Criteria:

  • Renal disease
  • Liver disease
  • Diabetes
  • Heart disease
  • Stroke
  • Cancer
  • Eating disorders
  • Thyroid disease
  • Gut-associated pathologies
  • diseases
  • Chronic inflammatory diseases
  • Scleroderma
  • Gallbladder disease
  • Blood clotting disorders
  • Intravenous drug use
  • Fasting plasma/serum triglycerides >500 mg/dL
  • Fasting plasma/serum glucose >126 mg/d
  • Weight changes >10% over last 4 weeks
  • Oral antibiotics use up to 1 month prior to and during study
  • Allergy or intolerance to milk products
  • Taking lipid-lowering medications (e.g., statins, fibrates)
  • Taking anti-inflammatory medications (e.g., )
  • Taking medications which primarily affect blood clotting (e.g., warfarin).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    MPL-rich dairy powder

    Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.

    Drug: Milk Polar Lipid-Rich Dairy Powder

  • Placebo comparator
    Control dairy powder

    Daily consumption of 50 g of dairy powder containing \<0.1 g MPL for 8 weeks

    Dietary Supplement: Dairy Powder

Interventions

  • DrugMilk Polar Lipid-Rich Dairy Powder

    Effects of the addition of 6.5 g of milk polar lipids to dairy powder.

  • Dietary supplementDairy Powder

    Effects of dairy control powder

06

What researchers measure

Primary outcomes

  1. Change from Baseline Serum LDL Cholesterol at 8 weeks

    Measurement of serum LDL cholesterol (mg/dL) at the beginning and end of 8-week intervention arm.

    Time frame: 8 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 83 phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 26, 2023
StartActual
Oct 20, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05700916
Collaborators
Dairy Management Inc.
Responsible party
Christopher Blesso (Associate Professor, University of Connecticut) — Principal investigator
First posted
Jan 26, 2023
Start date
Oct 20, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion